Pfizer submitted a New Drug Application for Paxlovid, its oral antiviral COVID-19 treatment, on June 30. The drug, which already has received emergency approval by the FDA, reduces the risk of ...

Paxlovid is an antiviral combination therapy that can reduce the risk of COVID-19 causing severe illness, hospitalization and ...

Federal regulators have authorized Pfizer’s antiviral pill, Paxlovid, to treat early symptoms of COVID-19.; The medication will be available to adults as well as children age 12 and older.

Pfizer and the FDA view Paxlovid as an important complementary tool to vaccination that can help high-risk Americans manage their Covid infections.

Pfizer’s COVID-19 pill Paxlovid won another vote of confidence from U.S. health advisers Thursday, clearing the way for its full regulatory approval by the Food ...

Pfizer will sell its COVID-19 antiviral treatment at more than twice the price at which it was sold to the federal government as it transitions toward the commercial market. Since Paxlovid was ...

June 7 (Reuters) - A 15-day course of Pfizer's , opens new tab COVID-19 antiviral treatment Paxlovid did not relieve symptoms of long COVID, according a study by Stanford University researchers.

To date, Pfizer has shipped 12 million courses of PAXLOVID across 37 countries, including 5 million courses shipped to the U.S., and has manufactured almost 17 million treatment courses total.

Pfizer announced on Thursday it has reached an agreement to supply up to six million courses of its COVID-19 antiviral Paxlovid to the Global Fund to get treatment to low and middle-income countries.

A 15-day course of Pfizer's COVID-19 antiviral treatment Paxlovid did not relieve symptoms of long COVID, according a study by Stanford University researchers. Currently, there are no proven ...